A light at the end of the tunnel of inflammation in obstructive airway diseases?
Gibson
Peter G
PG
Newcastle, NSW, Australia. Electronic address: Peter.Gibson@hnehealth.nsw.gov.au.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000393:Air Pollutants / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000627:therapeutic use; D023521:Chlamydophila Infections / Q000473:pathology / Q000503:physiopathology; D016993:Chlamydophila pneumoniae; D006801:Humans; D007113:Immunity, Innate / Q000502:physiology; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008173:Lung Diseases, Obstructive / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D009504:Neutrophils / Q000473:pathology* / Q000502:physiology; D011014:Pneumonia / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D012907:Smoking / Q000009:adverse effects
D000305:Adrenal Cortex Hormones; D000393:Air Pollutants; D000890:Anti-Infective Agents